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treatment PSA was 7.2 ng/ml (range, 0.8 to 19.9). The 
overall 3-year biochemical relapse free survival (bRFS) was 
93.9%. Cox regression identified primary gleason pattern as 
the only significant predictor of PSA relapse with a HR of 5.84 
(1.92 to 17.8, 95% CI) for primary gleason pattern 4 vs. 3. 
There was no significant difference in bRFS between patients 
classified as having favorable vs. unfavorable intermediate 
risk disease, HR 0.39 (0.11 to 1.41, 95% CI). There were no 
significant benefits observed with respect to ADT in any 
subgroup. 
 
Conclusion: Early PSA responses after SBRT for intermediate 
risk prostate adenocarcinoma compare favorably to those 
reported using other radiation therapy modalities. Primary 
gleason pattern 4 is predictive of less favorable bRFS, 
however early rates of PSA control are excellent compared to 
historical controls. The role of ADT in these patients is still 
unclear. The current evidence supports SBRT as a standard 
therapeutic option in intermediate risk disease. 
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Purpose or Objective: The aim of the study was to compare 
health-related quality of life (QoL) after external beam 
radiotherapy (RT) for prostate cancer with and without a 
hydrogel spacer. 
 
Material and Methods: A group of 202 patients with the 
indication for treatment of the prostate +/- base of seminal 
vesicles without pelvic lymph nodes was treated in a single 
institution in the years 2010-2013. Depending on the 
patient’s and responsible radiation oncologist’s preference, 
108 patients were selected for a hydrogel injection before 
the beginning of RT. The injection of 10 ml hydrogel was 
performed under transrectal ultrasound (TRUS) guidance 
after dissecting the space between prostate and rectum with 
a saline/lidocaine solution under local anaesthesia. 
Treatment was performed with a five-field IMRT or VMAT 
technique with daily ultrasound based image guidance. Only 
for patients with a spacer the prescription dose was 
increased from 76Gy to 78Gy, subsequently 80Gy. Patients 
were surveyed prospectively before RT (time A), at the last 
day of RT (time B), a median time of two months (time C) 
and seventeen months after RT (time D) using a validated 
questionnaire (Expanded Prostate Cancer Index Composite; 
comprising 50 items concerning urinary, bowel, sexual and 
hormonal domains). The multi-item scale scores were 
transformed lineary to a 0-100 scale, with higher scores 
representing better QoL. Baseline QoL assessment was 
available from 101 / 66 patients with / without a spacer. 
Responses to both the baseline and last (time D) 
questionnaire were available in 94 / 57 cases with / without 
a spacer. 
 
Results: Apart from higher prescription doses in the spacer 
group, baseline patient characteristics were well balanced 
between patients with vs. without a spacer (Table). In 
particular, baseline QoL was comparable. Acute toxicity 
(corresponding to QoL changes at times B and C relative to 
baseline levels) did not differ significantly, with only a 
tendency for better scores in the spacer group. However, 
mean bowel bother scores >1 year after RT in comparison to 
baseline did not change for patients with a spacer (mean 
change of 0 points) in contrast to patients without a spacer 
(mean decrease of 7 points). Long-term mean urinary bother 
scores did not decrease in both groups. At time D, 
statistically significant differences were found in the function 
items “bloody stools”, “painful bowel movements” and 
“frequency of bowel movements”. Focusing on patients with 
no problem with bowel symptoms initially, 0% vs. 12% with 
vs. without a spacer reported a moderate/big problem with 
bowel symptoms >1 year after RT (p<0.01). 
 
 
Conclusion: Though acute rectal symptoms are still reported, 
spacer injection is associated with a significant long-term 
benefit for patients after prostate cancer RT. 
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Purpose or Objective: To compare biochemical outcomes 
and toxicity of intensity modulated radiotherapy (IMRT) and 
three-dimensional conformal radiotherapy (3D-CRT) when 
used in combination with I-125 brachytherapy (BT) for the 
treatment of unfavorable-risk prostate cancer. 
 
Material and Methods: A retrospective review was performed 
on 839 patients with localized prostate cancer who received 
external-beam radiotherapy (EBRT) following BT between 
2003 and 2012. Patients were categorized into National 
Comprehensive Cancer Network risk groups: 616 were 
unfavorable intermediate-risk (Gleason score 4+3, or Gleason 
score 3+4 with positive biopsy core rate >1/3), and 223 were 
high-risk. Treatment begins with BT, followed 6 weeks later 
by 45 Gy/25 fractions of EBRT. EBRT was delivered via 3D-
CRT in 616 men at first and via IMRT technique for 223 men 
after 2010. The prescription dose for I-125 was 100 Gy, up to 
110 Gy after 2009. All patients underwent a CT scan for 
postplan dosimetry at day 30. The rectal volumes receiving 
doses higher than 30 Gy, 35 Gy, and 40Gy should be kept 
under 35%, 25%, and 15%, respectively. Neoadjuvant 
androgen deprivation therapy was given to 45% of patients. 
Biochemical failure was defined with the Phoenix criteria, 
and toxicity was graded according to the National Cancer 
Institute’s Common Terminology Criteria for Adverse Events, 
prospectively collected. The median (range) follow-up was 7 
(2-12) years for the entire cohort; 8.3 years for 3D-CRT, and 
4.3 years for IMRT. The biological effective dose (BED) was 
calculated using an α/β of 2 Gy and the D90 values of the 
prostate on a day-30 CT scan. Comparisons were made by 
chi-square test and log-rank test. 
 
Results: The total BED value of the prostate was higher in the 
IMRT group than in the 3D-CRT group (219 Gy2 vs. 209 Gy2, p 
<0.001). The 5-year actuarial freedom from biochemical 
failure for the IMRT group vs. the 3D-CRT group were 92.7% 
vs. 92.6% (p=0.825) for all; 95.4% vs. 95.1% for intermediate-
risk, and 88.0% vs. 84.8% for high-risk group (p=0.788), 
respectively. Acute gastrointestinal (GI) grade 2+ toxicities 
occurred in 0.5% of the IMRT group and 2.7% of the 3D-CRT 
